OxThera

About:

OxThera develops products for the treatment of metabolic disorders resulting from excess levels of oxalate.

Website: http://www.oxthera.com/

Top Investors: EQT Life Sciences, Kurma Partners, HealthCap, Industrifonden, Ysios Capital

Description:

OxThera is a biopharmaceutical company with products in late stage clinical development focusing on Primary and Secondary Hyperoxaluria. OxThera’s intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria, and enzymes. Oxabact® holds Orphan Drug designations in Europe and in the US for the treatment of primary hyperoxaluria.